GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...
The entrance to the Rolls Building, which houses the Business and Property Courts of England and Wales. A court in the UK has said that GSK should pay AstraZeneca a higher royalty rate on sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback